-
1
-
-
42049107348
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
-
10.1056/NEJMoa0801317, 18378520
-
Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-59. 10.1056/NEJMoa0801317, 18378520.
-
(2008)
N Engl J Med
, vol.358
, pp. 1547-1559
-
-
Yusuf, S.1
Teo, K.K.2
Pogue, J.3
Dyal, L.4
Copland, I.5
Schumacher, H.6
Dagenais, G.7
Sleight, P.8
Anderson, C.9
-
2
-
-
0034688194
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
-
10.1056/NEJM200001203420301, 10639539, The Heart Outcomes Prevention Evaluation Study Investigators
-
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, . The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-53. 10.1056/NEJM200001203420301, 10639539, The Heart Outcomes Prevention Evaluation Study Investigators.
-
(2000)
N Engl J Med
, vol.342
, pp. 145-153
-
-
Yusuf, S.1
Sleight, P.2
Pogue, J.3
Bosch, J.4
Davies, R.5
Dagenais, G.6
-
3
-
-
48649105160
-
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial
-
10.1016/S0140-6736(08)61193-9, 18757085, Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND®) Investigators
-
Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, . Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND®) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008, 372:1174-83. 10.1016/S0140-6736(08)61193-9, 18757085, Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND®) Investigators.
-
(2008)
Lancet
, vol.372
, pp. 1174-1183
-
-
Yusuf, S.1
Teo, K.2
Anderson, C.3
Pogue, J.4
Dyal, L.5
Copland, I.6
Schumacher, H.7
Dagenais, G.8
Sleight, P.9
-
4
-
-
67650070753
-
Effect of telmisartan on renal outcomes: a randomized trial
-
TRANSCEND® (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators
-
Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S, . TRANSCEND® (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009, 7:1-10. TRANSCEND® (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators.
-
(2009)
Ann Intern Med
, vol.7
, pp. 1-10
-
-
Mann, J.F.1
Schmieder, R.E.2
Dyal, L.3
McQueen, M.J.4
Schumacher, H.5
Pogue, J.6
Wang, X.7
Probstfield, J.L.8
Avezum, A.9
Cardona-Munoz, E.10
Dagenais, G.R.11
Diaz, R.12
Fodor, G.13
Maillon, J.M.14
Rydén, L.15
Yu, C.M.16
Teo, K.K.17
Yusuf, S.18
-
5
-
-
49149087718
-
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET® study): a multicentre, randomised, double-blind, controlled trial
-
10.1016/S0140-6736(08)61236-2, 18707986, The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) Investigators
-
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, . The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) Investigators Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET® study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-53. 10.1016/S0140-6736(08)61236-2, 18707986, The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) Investigators.
-
(2008)
Lancet
, vol.372
, pp. 547-553
-
-
Mann, J.F.1
Schmieder, R.E.2
McQueen, M.3
Dyal, L.4
Schumacher, H.5
Pogue, J.6
Wang, X.7
Maggioni, A.8
Budaj, A.9
Chaithiraphan, S.10
Dickstein, K.11
Keltai, M.12
Metsärinne, K.13
Oto, A.14
Parkhomenko, A.15
Piegas, L.S.16
Svendsen, T.L.17
Teo, K.K.18
Yusuf, S.19
-
6
-
-
0033574249
-
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation
-
Modification of Diet in Renal Disease Study Group
-
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, . Modification of Diet in Renal Disease Study Group A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999, 130:461-70. Modification of Diet in Renal Disease Study Group.
-
(1999)
Ann Intern Med
, vol.130
, pp. 461-470
-
-
Levey, A.S.1
Bosch, J.P.2
Lewis, J.B.3
Greene, T.4
Rogers, N.5
Roth, D.6
-
7
-
-
33744958852
-
Assessing kidney function--measured and estimated glomerular filtration rate
-
10.1056/NEJMra054415, 16760447
-
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med 2006, 354:2473-83. 10.1056/NEJMra054415, 16760447.
-
(2006)
N Engl J Med
, vol.354
, pp. 2473-2483
-
-
Stevens, L.A.1
Coresh, J.2
Greene, T.3
Levey, A.S.4
-
8
-
-
65649142017
-
A new equation to estimate glomerular filtration rate
-
2763564, 19414839, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
-
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, . CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-12. 2763564, 19414839, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).
-
(2009)
Ann Intern Med
, vol.150
, pp. 604-612
-
-
Levey, A.S.1
Stevens, L.A.2
Schmid, C.H.3
Zhang, Y.L.4
Castro, A.F.5
Feldman, H.I.6
Kusek, J.W.7
Eggers, P.8
Van Lente, F.9
Greene, T.10
Coresh, J.11
-
9
-
-
18644370841
-
Cystatin C and the risk of death and cardiovascular events among elderly persons
-
10.1056/NEJMoa043161, 15901858
-
Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005, 352:2049-60. 10.1056/NEJMoa043161, 15901858.
-
(2005)
N Engl J Med
, vol.352
, pp. 2049-2060
-
-
Shlipak, M.G.1
Sarnak, M.J.2
Katz, R.3
Fried, L.F.4
Seliger, S.L.5
Newman, A.B.6
Siscovick, D.S.7
Stehman-Breen, C.8
-
10
-
-
27444435483
-
Screening techniques for detecting chronic kidney disease
-
10.1097/01.mnh.0000183948.13739.ee, 16205477
-
de Jong PE, Gansevoort RT. Screening techniques for detecting chronic kidney disease. Curr Opin Nephrol Hypertens 2005, 14:567-72. 10.1097/01.mnh.0000183948.13739.ee, 16205477.
-
(2005)
Curr Opin Nephrol Hypertens
, vol.14
, pp. 567-572
-
-
de Jong, P.E.1
Gansevoort, R.T.2
-
11
-
-
1042302788
-
Nephropathy in diabetes
-
American Diabetes Association
-
American Diabetes Association Nephropathy in diabetes. Diabetes Care 2004, 27(Suppl 1):S79-S83. American Diabetes Association.
-
(2004)
Diabetes Care
, vol.27
, Issue.SUPPL 1
-
-
-
12
-
-
67650451498
-
Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration
-
10.1053/j.ajkd.2009.04.029, 19577347
-
Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T. Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009, 54:205-226. 10.1053/j.ajkd.2009.04.029, 19577347.
-
(2009)
Am J Kidney Dis
, vol.54
, pp. 205-226
-
-
Levey, A.S.1
Cattran, D.2
Friedman, A.3
Miller, W.G.4
Sedor, J.5
Tuttle, K.6
Kasiske, B.7
Hostetter, T.8
-
13
-
-
65349131482
-
Prevalence of albuminuria and renal insufficiency in type 2 diabetes: the Japanese Diabetes Clinical Data Management study (JDDM15)
-
10.1093/ndt/gfn603, 18984626, Japan Diabetes Clinical Data Management Study Group
-
Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M, . Japan Diabetes Clinical Data Management Study Group Prevalence of albuminuria and renal insufficiency in type 2 diabetes: the Japanese Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009, 24:1212-19. 10.1093/ndt/gfn603, 18984626, Japan Diabetes Clinical Data Management Study Group.
-
(2009)
Nephrol Dial Transplant
, vol.24
, pp. 1212-1219
-
-
Yokoyama, H.1
Sone, H.2
Oishi, M.3
Kawai, K.4
Fukumoto, Y.5
Kobayashi, M.6
-
14
-
-
0037378449
-
Proteinuria and the risk of developing end-stage renal disease
-
10.1046/j.1523-1755.2003.00868.x, 12631363
-
Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003, 63:1468-74. 10.1046/j.1523-1755.2003.00868.x, 12631363.
-
(2003)
Kidney Int
, vol.63
, pp. 1468-1474
-
-
Iseki, K.1
Ikemiya, Y.2
Iseki, C.3
Takishita, S.4
-
15
-
-
33745318050
-
Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial
-
10.1136/bmj.38814.566019.2F, 1479622, 16714328, Cholesterol and Recurrent Events (CARE) Trial Investigators
-
Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M, . Cholesterol and Recurrent Events (CARE) Trial Investigators Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006, 332:1426. 10.1136/bmj.38814.566019.2F, 1479622, 16714328, Cholesterol and Recurrent Events (CARE) Trial Investigators.
-
(2006)
BMJ
, vol.332
, pp. 1426
-
-
Tonelli, M.1
Jose, P.2
Curhan, G.3
Sacks, F.4
Braunwald, E.5
Pfeffer, M.6
-
16
-
-
0037213037
-
Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)
-
10.1046/j.1523-1755.2003.00712.x, 12472787, UKPDS GROUP
-
Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, . UKPDS GROUP Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-32. 10.1046/j.1523-1755.2003.00712.x, 12472787, UKPDS GROUP.
-
(2003)
Kidney Int
, vol.63
, pp. 225-232
-
-
Adler, A.I.1
Stevens, R.J.2
Manley, S.E.3
Bilous, R.W.4
Cull, C.A.5
Holman, R.R.6
-
17
-
-
1642413198
-
Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization
-
10.1001/archinte.164.6.659, 15037495
-
Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-63. 10.1001/archinte.164.6.659, 15037495.
-
(2004)
Arch Intern Med
, vol.164
, pp. 659-663
-
-
Keith, D.S.1
Nichols, G.A.2
Gullion, C.M.3
Brown, J.B.4
Smith, D.H.5
-
18
-
-
45849099504
-
Comorbidities in UK patients at the start of renal replacement therapy
-
10.1093/ndt/gfm330, 17724052
-
Tomson C, Udayaraj U, Gilg J, Ansell D. Comorbidities in UK patients at the start of renal replacement therapy. Nephrol Dial Transplant 2007, 22(Suppl 7):vii58-vii68. 10.1093/ndt/gfm330, 17724052.
-
(2007)
Nephrol Dial Transplant
, vol.22
, Issue.SUPPL 7
-
-
Tomson, C.1
Udayaraj, U.2
Gilg, J.3
Ansell, D.4
-
19
-
-
0032916219
-
Cardiovascular mortality and morbidity in dialysis patients
-
10.1159/000057429, 10207269
-
Eknoyan G. Cardiovascular mortality and morbidity in dialysis patients. Miner Electrolyte Metab 1999, 25:100-104. 10.1159/000057429, 10207269.
-
(1999)
Miner Electrolyte Metab
, vol.25
, pp. 100-104
-
-
Eknoyan, G.1
-
20
-
-
0035901585
-
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial
-
Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-36.
-
(2001)
Ann Intern Med
, vol.134
, pp. 629-636
-
-
Mann, J.F.1
Gerstein, H.C.2
Pogue, J.3
Bosch, J.4
Yusuf, S.5
-
21
-
-
34548420712
-
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
-
10.1016/S0140-6736(07)61303-8, 17765963, ADVANCE Collaborative Group
-
Patel A, . ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370:829-40. 10.1016/S0140-6736(07)61303-8, 17765963, ADVANCE Collaborative Group.
-
(2007)
Lancet
, vol.370
, pp. 829-840
-
-
Patel, A.1
-
22
-
-
16644366851
-
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study
-
Review
-
Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Kidney Int Suppl 2004, Review:S56-S58.
-
(2004)
Kidney Int Suppl
-
-
Ibsen, H.1
Wachtell, K.2
Olsen, M.H.3
Borch-Johnsen, K.4
Lindholm, L.H.5
Mogensen, C.E.6
Dahlöf, B.7
-
23
-
-
34347254676
-
The Framingham Risk Score: an appraisal of its benefits and limitations
-
10.1111/j.1541-9215.2007.06350.x, 17478974
-
Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J 2007, 5:91-96. 10.1111/j.1541-9215.2007.06350.x, 17478974.
-
(2007)
Am Heart Hosp J
, vol.5
, pp. 91-96
-
-
Hemann, B.A.1
Bimson, W.F.2
Taylor, A.J.3
-
24
-
-
0034837376
-
Cardiovascular morbidity and mortality associated with the metabolic syndrome
-
10.2337/diacare.24.4.683, 11315831
-
Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-89. 10.2337/diacare.24.4.683, 11315831.
-
(2001)
Diabetes Care
, vol.24
, pp. 683-689
-
-
Isomaa, B.1
Almgren, P.2
Tuomi, T.3
Forsén, B.4
Lahti, K.5
Nissén, M.6
Taskinen, M.R.7
Groop, L.8
-
25
-
-
0037334224
-
Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk
-
10.1016/S0140-6736(03)12655-4, 12620735
-
Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003, 361:717-25. 10.1016/S0140-6736(03)12655-4, 12620735.
-
(2003)
Lancet
, vol.361
, pp. 717-725
-
-
Murray, C.J.1
Lauer, J.A.2
Hutubessy, R.C.3
Niessen, L.4
Tomijima, N.5
Rodgers, A.6
Lawes, C.M.7
Evans, D.B.8
-
26
-
-
0036176161
-
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification
-
National Kidney Foundation
-
National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-S266. National Kidney Foundation.
-
(2002)
Am J Kidney Dis
, vol.39
, Issue.2 SUPPL 1
-
-
-
27
-
-
0042830443
-
Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure
-
10.1046/j.1365-2796.2003.01207.x, 12930230
-
Tryggvason K, Pettersson E. Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med 2003, 254:216-24. 10.1046/j.1365-2796.2003.01207.x, 12930230.
-
(2003)
J Intern Med
, vol.254
, pp. 216-224
-
-
Tryggvason, K.1
Pettersson, E.2
-
28
-
-
33947226955
-
Cellular and molecular biology of membranous nephropathy
-
Couser WG, Nangaku M. Cellular and molecular biology of membranous nephropathy. J Nephrol 2006, 19:699-705.
-
(2006)
J Nephrol
, vol.19
, pp. 699-705
-
-
Couser, W.G.1
Nangaku, M.2
-
29
-
-
23044501315
-
Endothelial dysfunction is correlated with microalbuminuria in children with short-duration type 1 diabetes
-
10.2337/diacare.28.8.2048, 16043758
-
Ladeia AM, Ladeia-Frota C, Pinho L, Stefanelli E, Adan L. Endothelial dysfunction is correlated with microalbuminuria in children with short-duration type 1 diabetes. Diabetes Care 2005, 28:2048-50. 10.2337/diacare.28.8.2048, 16043758.
-
(2005)
Diabetes Care
, vol.28
, pp. 2048-2050
-
-
Ladeia, A.M.1
Ladeia-Frota, C.2
Pinho, L.3
Stefanelli, E.4
Adan, L.5
-
30
-
-
77952109980
-
The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study
-
10.1186/1475-2840-9-18, 2877657, 20470427
-
Ito H, Komatsu Y, Mifune M, Antoku S, Ishida H, Takeuchi Y, Togane M. The estimated GFR, but not the stage of diabetic nephropathy graded by the urinary albumin excretion, is associated with the carotid intima-media thickness in patients with type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol 2010, 9:18. 10.1186/1475-2840-9-18, 2877657, 20470427.
-
(2010)
Cardiovasc Diabetol
, vol.9
, pp. 18
-
-
Ito, H.1
Komatsu, Y.2
Mifune, M.3
Antoku, S.4
Ishida, H.5
Takeuchi, Y.6
Togane, M.7
-
31
-
-
0031788869
-
Mechanism of progression of renal disease: current hemodynamic concepts
-
10.1097/00004872-199816010-00002, 9817185
-
Johnston CI, Risvanis J, Naitoh M, Tikkanen I. Mechanism of progression of renal disease: current hemodynamic concepts. J Hypertens Suppl 1998, 16:S3-S7. 10.1097/00004872-199816010-00002, 9817185.
-
(1998)
J Hypertens Suppl
, vol.16
-
-
Johnston, C.I.1
Risvanis, J.2
Naitoh, M.3
Tikkanen, I.4
-
32
-
-
0033007050
-
The impact of a family history of Type II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with Type I (insulin-dependent) diabetes mellitus
-
10.1007/s001250051189, 10333042
-
Fagerudd JA, Pettersson-Fernholm KJ, Gronhagen-Riska C, Groop PH. The impact of a family history of Type II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with Type I (insulin-dependent) diabetes mellitus. Diabetologia 1999, 42:519-26. 10.1007/s001250051189, 10333042.
-
(1999)
Diabetologia
, vol.42
, pp. 519-526
-
-
Fagerudd, J.A.1
Pettersson-Fernholm, K.J.2
Gronhagen-Riska, C.3
Groop, P.H.4
-
33
-
-
0242383894
-
Lifestyle risk factors and chronic kidney disease
-
10.1016/S1047-2797(03)00066-8, 14599736
-
Vupputuri S, Sandler DP. Lifestyle risk factors and chronic kidney disease. Ann Epidemiol 2003, 13:712-20. 10.1016/S1047-2797(03)00066-8, 14599736.
-
(2003)
Ann Epidemiol
, vol.13
, pp. 712-720
-
-
Vupputuri, S.1
Sandler, D.P.2
-
34
-
-
33644790793
-
Microalbuminuria and lower glomerular filtration rate at young adult age in subjects born very premature and after intrauterine growth retardation
-
10.1681/ASN.2004090783, 15987756, Dutch POPS-19 Collaborative Study Group
-
Keijzer-Veen MG, Schrevel M, Finken MJ, Dekker FW, Nauta J, Hille ET, Frölich M, van der Heijden BJ, . Dutch POPS-19 Collaborative Study Group Microalbuminuria and lower glomerular filtration rate at young adult age in subjects born very premature and after intrauterine growth retardation. J Am Soc Nephrol 2005, 16:2762-68. 10.1681/ASN.2004090783, 15987756, Dutch POPS-19 Collaborative Study Group.
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 2762-2768
-
-
Keijzer-Veen, M.G.1
Schrevel, M.2
Finken, M.J.3
Dekker, F.W.4
Nauta, J.5
Hille, E.T.6
Frölich, M.7
van der Heijden, B.J.8
-
35
-
-
39349106654
-
Low birth weight is associated with chronic kidney disease only in men
-
10.1038/sj.ki.5002747, 18094674, Kidney Early Evaluation Program Investigators
-
Li S, Chen SC, Shlipak M, Bakris G, McCullough PA, Sowers J, Stevens L, Jurkovitz C, McFarlane S, Norris K, Vassalotti J, Klag MJ, Brown WW, Narva A, Calhoun D, Johnson B, Obialo C, Whaley-Connell A, Becker B, Collins AJ, . Kidney Early Evaluation Program Investigators Low birth weight is associated with chronic kidney disease only in men. Kidney Int 2008, 73:637-42. 10.1038/sj.ki.5002747, 18094674, Kidney Early Evaluation Program Investigators.
-
(2008)
Kidney Int
, vol.73
, pp. 637-642
-
-
Li, S.1
Chen, S.C.2
Shlipak, M.3
Bakris, G.4
McCullough, P.A.5
Sowers, J.6
Stevens, L.7
Jurkovitz, C.8
McFarlane, S.9
Norris, K.10
Vassalotti, J.11
Klag, M.J.12
Brown, W.W.13
Narva, A.14
Calhoun, D.15
Johnson, B.16
Obialo, C.17
Whaley-Connell, A.18
Becker, B.19
Collins, A.J.20
more..
-
36
-
-
38149131097
-
Low birth weight increases risk for end-stage renal disease
-
10.1681/ASN.2007020252, 2391041, 18057216
-
Vikse BE, Irgens LM, Leivestad T, Hallan S, Iversen BM. Low birth weight increases risk for end-stage renal disease. J Am Soc Nephrol 2008, 19:151-57. 10.1681/ASN.2007020252, 2391041, 18057216.
-
(2008)
J Am Soc Nephrol
, vol.19
, pp. 151-157
-
-
Vikse, B.E.1
Irgens, L.M.2
Leivestad, T.3
Hallan, S.4
Iversen, B.M.5
-
37
-
-
27744594622
-
Long-term consequences of low birth weight
-
10.1111/j.1523-1755.2005.09718.x, 16014086
-
Reyes L, Manalich R. Long-term consequences of low birth weight. Kidney Int Suppl 2005, (Suppl):S107-S111. 10.1111/j.1523-1755.2005.09718.x, 16014086.
-
(2005)
Kidney Int Suppl
, Issue.SUPPL
-
-
Reyes, L.1
Manalich, R.2
-
38
-
-
49649119083
-
Evidence of arteriolar narrowing in low-birth-weight children
-
10.1161/CIRCULATIONAHA.107.747329, 18625895
-
Mitchell P, Liew G, Rochtchina E, Wang JJ, Robaei D, Cheung N, Wong TY. Evidence of arteriolar narrowing in low-birth-weight children. Circulation 2008, 118:518-24. 10.1161/CIRCULATIONAHA.107.747329, 18625895.
-
(2008)
Circulation
, vol.118
, pp. 518-524
-
-
Mitchell, P.1
Liew, G.2
Rochtchina, E.3
Wang, J.J.4
Robaei, D.5
Cheung, N.6
Wong, T.Y.7
-
39
-
-
42049114695
-
Low birthweight is associated with narrower arterioles in adults
-
10.1161/HYPERTENSIONAHA.107.101584, 18268137, Atherosclerosis Risk in Communities Study
-
Liew G, Wang JJ, Duncan BB, Klein R, Sharrett AR, Brancati F, Yeh HC, Mitchell P, Wong TY, . Atherosclerosis Risk in Communities Study Low birthweight is associated with narrower arterioles in adults. Hypertension 2008, 51:933-38. 10.1161/HYPERTENSIONAHA.107.101584, 18268137, Atherosclerosis Risk in Communities Study.
-
(2008)
Hypertension
, vol.51
, pp. 933-938
-
-
Liew, G.1
Wang, J.J.2
Duncan, B.B.3
Klein, R.4
Sharrett, A.R.5
Brancati, F.6
Yeh, H.C.7
Mitchell, P.8
Wong, T.Y.9
-
40
-
-
0034732256
-
Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study
-
10.1056/NEJM200003303421301, 10738048
-
Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-12. 10.1056/NEJM200003303421301, 10738048.
-
(2000)
N Engl J Med
, vol.342
, pp. 905-912
-
-
Gress, T.W.1
Nieto, F.J.2
Shahar, E.3
Wofford, M.R.4
Brancati, F.L.5
-
41
-
-
17644378057
-
Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease
-
10.1001/archinte.165.8.923, 15851645
-
Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005, 165:923-28. 10.1001/archinte.165.8.923, 15851645.
-
(2005)
Arch Intern Med
, vol.165
, pp. 923-928
-
-
Hsu, C.Y.1
McCulloch, C.E.2
Darbinian, J.3
Go, A.S.4
Iribarren, C.5
-
42
-
-
0014456533
-
The consomitants of raised blood sugar: studies in newly-detected hyperglycaemics. II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels
-
Keen H, Chlouverakis C, Fuller J, Jarrett RJ. The consomitants of raised blood sugar: studies in newly-detected hyperglycaemics. II. Urinary albumin excretion, blood pressure and their relation to blood sugar levels. Guys Hosp Rep 1969, 118:247-54.
-
(1969)
Guys Hosp Rep
, vol.118
, pp. 247-254
-
-
Keen, H.1
Chlouverakis, C.2
Fuller, J.3
Jarrett, R.J.4
-
43
-
-
0038188642
-
Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy
-
10.1046/j.1523-1755.2003.00007.x, 12753303
-
Janssen U, Riley SG, Vassiliadou A, Floege J, Phillips AO. Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int 2003, 63:2162-70. 10.1046/j.1523-1755.2003.00007.x, 12753303.
-
(2003)
Kidney Int
, vol.63
, pp. 2162-2170
-
-
Janssen, U.1
Riley, S.G.2
Vassiliadou, A.3
Floege, J.4
Phillips, A.O.5
-
44
-
-
0028215329
-
The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group
-
10.1056/NEJM199403313301301, 8114857
-
Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994, 330:877-84. 10.1056/NEJM199403313301301, 8114857.
-
(1994)
N Engl J Med
, vol.330
, pp. 877-884
-
-
Klahr, S.1
Levey, A.S.2
Beck, G.J.3
Caggiula, A.W.4
Hunsicker, L.5
Kusek, J.W.6
Striker, G.7
-
45
-
-
14344255910
-
The effect of lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study
-
Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS. The effect of lower target blood pressure on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med 2005, 142:342-51.
-
(2005)
Ann Intern Med
, vol.142
, pp. 342-351
-
-
Sarnak, M.J.1
Greene, T.2
Wang, X.3
Beck, G.4
Kusek, J.W.5
Collins, A.J.6
Levey, A.S.7
-
46
-
-
0036190137
-
Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes
-
10.1046/j.1523-1755.2002.00213.x, 11849464
-
Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002, 61:1086-97. 10.1046/j.1523-1755.2002.00213.x, 11849464.
-
(2002)
Kidney Int
, vol.61
, pp. 1086-1097
-
-
Schrier, R.W.1
Estacio, R.O.2
Esler, A.3
Mehler, P.4
-
47
-
-
77958153990
-
Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: Results of the ADVANCE trial
-
ADVANCE Collaborative Group
-
de Galan BE, Chalmers J, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, MacMahon S, Neal B, Mogensen CE, Marre M, Harrap SB, Poulter NR, Cooper ME, Mancia G, . ADVANCE Collaborative Group Renoprotection with perindopril-indapamide below current recommended blood pressure targets in patients with type 2 diabetes mellitus: Results of the ADVANCE trial. J Hypertens 2008, 26(Suppl 1):S188-S189. ADVANCE Collaborative Group.
-
(2008)
J Hypertens
, vol.26
, Issue.SUPPL 1
-
-
de Galan, B.E.1
Chalmers, J.2
Perkovic, V.3
Ninomiya, T.4
Pillai, A.5
Patel, A.6
Cass, A.7
MacMahon, S.8
Neal, B.9
Mogensen, C.E.10
Marre, M.11
Harrap, S.B.12
Poulter, N.R.13
Cooper, M.E.14
Mancia, G.15
-
48
-
-
33644912981
-
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations
-
10.1681/ASN.2004110919, 16120823
-
Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005, 16:3027-37. 10.1681/ASN.2004110919, 16120823.
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 3027-3037
-
-
Pohl, M.A.1
Blumenthal, S.2
Cordonnier, D.J.3
De Alvaro, F.4
Deferrari, G.5
Eisner, G.6
Esmatjes, E.7
Gilbert, R.E.8
Hunsicker, L.G.9
de Faria, J.B.10
Mangili, R.11
Moore, J.12
Reisin, E.13
Ritz, E.14
Schernthaner, G.15
Spitalewitz, S.16
Tindall, H.17
Rodby, R.A.18
Lewis, E.J.19
-
49
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
-
10.1056/NEJMoa011303, 11565517, Collaborative Study Group
-
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, . Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-60. 10.1056/NEJMoa011303, 11565517, Collaborative Study Group.
-
(2001)
N Engl J Med
, vol.345
, pp. 851-860
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
Berl, T.4
Pohl, M.A.5
Lewis, J.B.6
Ritz, E.7
Atkins, R.C.8
Rohde, R.9
Raz, I.10
-
50
-
-
77951735232
-
Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
-
The ACCORD Study Group
-
The ACCORD Study Group Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 2010, 17:1575-85. The ACCORD Study Group.
-
(2010)
N Engl J Med
, vol.17
, pp. 1575-1585
-
-
-
51
-
-
34250350040
-
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
-
10.1097/HJH.0b013e3281fc975a, 17563527, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology
-
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B, . Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-87. 10.1097/HJH.0b013e3281fc975a, 17563527, Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology.
-
(2007)
J Hypertens
, vol.25
, pp. 1105-1187
-
-
Mancia, G.1
De Backer, G.2
Dominiczak, A.3
Cifkova, R.4
Fagard, R.5
Germano, G.6
Grassi, G.7
Heagerty, A.M.8
Kjeldsen, S.E.9
Laurent, S.10
Narkiewicz, K.11
Ruilope, L.12
Rynkiewicz, A.13
Schmieder, R.E.14
Boudier, H.A.15
Zanchetti, A.16
Vahanian, A.17
Camm, J.18
De Caterina, R.19
Dean, V.20
Dickstein, K.21
Filippatos, G.22
Funck-Brentano, C.23
Hellemans, I.24
Kristensen, S.D.25
McGregor, K.26
Sechtem, U.27
Silber, S.28
Tendera, M.29
Widimsky, P.30
Zamorano, J.L.31
Erdine, S.32
Kiowski, W.33
Agabiti-Rosei, E.34
Ambrosioni, E.35
Lindholm, L.H.36
Viigimaa, M.37
Adamopoulos, S.38
Agabiti-Rosei, E.39
Ambrosioni, E.40
Bertomeu, V.41
Clement, D.42
Erdine, S.43
Farsang, C.44
Gaita, D.45
Lip, G.46
Mallion, J.M.47
Manolis, A.J.48
Nilsson, P.M.49
O'Brien, E.50
Ponikowski, P.51
Redon, J.52
Ruschitzka, F.53
Tamargo, J.54
van Zwieten, P.55
Waeber, B.56
Williams, B.57
more..
-
52
-
-
33646156403
-
Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure
-
10.1161/01.HYP.0000215363.69793.bb, 16567588
-
Mancia G, Facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006, 47:846-53. 10.1161/01.HYP.0000215363.69793.bb, 16567588.
-
(2006)
Hypertension
, vol.47
, pp. 846-853
-
-
Mancia, G.1
Facchetti, R.2
Bombelli, M.3
Grassi, G.4
Sega, R.5
-
53
-
-
33646137566
-
Office and ambulatory blood pressure are independently associated with albuminuria in older subjects with type 2 diabetes
-
10.1161/01.HYP.0000216634.73504.7d, 16585416
-
Moran A, Palmas W, Pickering TG, Schwartz JE, Field L, Weinstock RS, Shea S. Office and ambulatory blood pressure are independently associated with albuminuria in older subjects with type 2 diabetes. Hypertension 2006, 47:955-61. 10.1161/01.HYP.0000216634.73504.7d, 16585416.
-
(2006)
Hypertension
, vol.47
, pp. 955-961
-
-
Moran, A.1
Palmas, W.2
Pickering, T.G.3
Schwartz, J.E.4
Field, L.5
Weinstock, R.S.6
Shea, S.7
-
54
-
-
27844568135
-
Early changes in 24-hour ambulatory blood pressure are associated with high normal albumin excretion rate in children with type 1 diabetes mellitus
-
Gallego PH, Gilbey AJ, Grant MT, Bulsara MK, Byme GC, Jones TW, Frazer FL. Early changes in 24-hour ambulatory blood pressure are associated with high normal albumin excretion rate in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2005, 18:879-85.
-
(2005)
J Pediatr Endocrinol Metab
, vol.18
, pp. 879-885
-
-
Gallego, P.H.1
Gilbey, A.J.2
Grant, M.T.3
Bulsara, M.K.4
Byme, G.C.5
Jones, T.W.6
Frazer, F.L.7
-
55
-
-
40049112460
-
Nocturnal blood pressure elevation predicts progression of albuminuria in elderly people with type 2 diabetes
-
10.1111/j.1524-6175.2007.07170.x, 18174766
-
Palmas W, Pickering T, Teresi J, Schwartz JE, Eguchi K, Field L, Weinstock RS, Shea S. Nocturnal blood pressure elevation predicts progression of albuminuria in elderly people with type 2 diabetes. J Clin Hypertens (Greenwich) 2008, 10:12-20. 10.1111/j.1524-6175.2007.07170.x, 18174766.
-
(2008)
J Clin Hypertens (Greenwich)
, vol.10
, pp. 12-20
-
-
Palmas, W.1
Pickering, T.2
Teresi, J.3
Schwartz, J.E.4
Eguchi, K.5
Field, L.6
Weinstock, R.S.7
Shea, S.8
-
56
-
-
18844449196
-
Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes
-
10.1097/01.hjh.0000160198.05416.72, 15716683
-
Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005, 23:463-73. 10.1097/01.hjh.0000160198.05416.72, 15716683.
-
(2005)
J Hypertens
, vol.23
, pp. 463-473
-
-
Jandeleit-Dahm, K.A.1
Tikellis, C.2
Reid, C.M.3
Johnston, C.I.4
Cooper, M.E.5
-
57
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
10.1056/NEJMoa011161, 11565518, RENAAL Study Investigators
-
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, . RENAAL Study Investigators Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-69. 10.1056/NEJMoa011161, 11565518, RENAAL Study Investigators.
-
(2001)
N Engl J Med
, vol.345
, pp. 861-869
-
-
Brenner, B.M.1
Cooper, M.E.2
de Zeeuw, D.3
Keane, W.F.4
Mitch, W.E.5
Parving, H.H.6
Remuzzi, G.7
Snapinn, S.M.8
Zhang, Z.9
Shahinfar, S.10
-
59
-
-
67649659279
-
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials
-
Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009, 151:11-20.
-
(2009)
Ann Intern Med
, vol.151
, pp. 11-20
-
-
Bilous, R.1
Chaturvedi, N.2
Sjølie, A.K.3
Fuller, J.4
Klein, R.5
Orchard, T.6
Porta, M.7
Parving, H.H.8
-
60
-
-
67649635807
-
Renal and retinal effects of enalapril and losartan in type 1 diabetes
-
10.1056/NEJMoa0808400, 19571282
-
Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009, 361:40-51. 10.1056/NEJMoa0808400, 19571282.
-
(2009)
N Engl J Med
, vol.361
, pp. 40-51
-
-
Mauer, M.1
Zinman, B.2
Gardiner, R.3
Suissa, S.4
Sinaiko, A.5
Strand, T.6
Drummond, K.7
Donnelly, S.8
Goodyer, P.9
Gubler, M.C.10
Klein, R.11
-
61
-
-
8144224441
-
Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria
-
10.1161/01.CIR.0000146378.65439.7A, 15492322
-
Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004, 110:2809-16. 10.1161/01.CIR.0000146378.65439.7A, 15492322.
-
(2004)
Circulation
, vol.110
, pp. 2809-2816
-
-
Asselbergs, F.W.1
Diercks, G.F.2
Hillege, H.L.3
van Boven, A.J.4
Janssen, W.M.5
Voors, A.A.6
de Zeeuw, D.7
de Jong, P.E.8
van Veldhuisen, D.J.9
van Gilst, W.H.10
-
62
-
-
2442680120
-
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL
-
10.1111/j.1523-1755.2004.00653.x, 15149345
-
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004, 65:2309-20. 10.1111/j.1523-1755.2004.00653.x, 15149345.
-
(2004)
Kidney Int
, vol.65
, pp. 2309-2320
-
-
de Zeeuw, D.1
Remuzzi, G.2
Parving, H.H.3
Keane, W.F.4
Zhang, Z.5
Shahinfar, S.6
Snapinn, S.7
Cooper, M.E.8
Mitch, W.E.9
Brenner, B.M.10
-
63
-
-
4344621497
-
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
-
10.1161/01.CIR.0000139860.33974.28, 15302780
-
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004, 110:921-27. 10.1161/01.CIR.0000139860.33974.28, 15302780.
-
(2004)
Circulation
, vol.110
, pp. 921-927
-
-
de Zeeuw, D.1
Remuzzi, G.2
Parving, H.H.3
Keane, W.F.4
Zhang, Z.5
Shahinfar, S.6
Snapinn, S.7
Cooper, M.E.8
Mitch, W.E.9
Brenner, B.M.10
-
64
-
-
0041332950
-
The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme
-
Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens 2003, 21(Suppl 6):S37-S46.
-
(2003)
J Hypertens
, vol.21
, Issue.SUPPL 6
-
-
Weber, M.1
-
65
-
-
34249869003
-
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes
-
10.2337/dc06-1551, 17337492
-
Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope LM. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007, 30:1351-56. 10.2337/dc06-1551, 17337492.
-
(2007)
Diabetes Care
, vol.30
, pp. 1351-1356
-
-
Schmieder, R.E.1
Delles, C.2
Mimran, A.3
Fauvel, J.P.4
Ruilope, L.M.5
-
66
-
-
34249899918
-
Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes
-
10.2337/dc06-1998, 17389334, INNOVATION Study Group
-
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S, . INNOVATION Study Group Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007, 30:1577-78. 10.2337/dc06-1998, 17389334, INNOVATION Study Group.
-
(2007)
Diabetes Care
, vol.30
, pp. 1577-1578
-
-
Makino, H.1
Haneda, M.2
Babazono, T.3
Moriya, T.4
Ito, S.5
Iwamoto, Y.6
Kawamori, R.7
Takeuchi, M.8
Katayama, S.9
-
67
-
-
7444237666
-
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy
-
10.1056/NEJMoa042274, 15516696, Diabetics Exposed to Telmisartan and Enalapril Study Group
-
Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, . Diabetics Exposed to Telmisartan and Enalapril Study Group Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004, 351:1952-61. 10.1056/NEJMoa042274, 15516696, Diabetics Exposed to Telmisartan and Enalapril Study Group.
-
(2004)
N Engl J Med
, vol.351
, pp. 1952-1961
-
-
Barnett, A.H.1
Bain, S.C.2
Bouter, P.3
Karlberg, B.4
Madsbad, S.5
Jervell, J.6
Mustonen, J.7
-
68
-
-
18744395241
-
Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL®) study
-
10.1007/s00592-005-0180-4, 15868119
-
Barnett AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL®) study. Acta Diabetol 2005, 42(Suppl 1):S42-S49. 10.1007/s00592-005-0180-4, 15868119.
-
(2005)
Acta Diabetol
, vol.42
, Issue.SUPPL 1
-
-
Barnett, A.H.1
-
69
-
-
0035922444
-
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
-
10.1056/NEJMoa011489, 11565519, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
-
Parving HH, Lehnert H, Broechner-Mortensen J, Gomis R, Andersen S, Arner P, . Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-78. 10.1056/NEJMoa011489, 11565519, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.
-
(2001)
N Engl J Med
, vol.345
, pp. 870-878
-
-
Parving, H.H.1
Lehnert, H.2
Broechner-Mortensen, J.3
Gomis, R.4
Andersen, S.5
Arner, P.6
-
70
-
-
48949118159
-
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy
-
10.1038/ki.2008.204, 18496508
-
Bakris G, Burgess E, Weir M, Davidai G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008, 74:364-69. 10.1038/ki.2008.204, 18496508.
-
(2008)
Kidney Int
, vol.74
, pp. 364-369
-
-
Bakris, G.1
Burgess, E.2
Weir, M.3
Davidai, G.4
Koval, S.5
-
71
-
-
52649110647
-
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy
-
10.1093/ndt/gfn230, 18450829
-
Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008, 23:3174-83. 10.1093/ndt/gfn230, 18450829.
-
(2008)
Nephrol Dial Transplant
, vol.23
, pp. 3174-3183
-
-
Galle, J.1
Schwedhelm, E.2
Pinnetti, S.3
Boger, R.H.4
Wanner, C.5
-
72
-
-
0030905088
-
Geriatric renal function: estimating glomerular filtration in an ambulatory elderly population
-
Baracskay D, Jarjoura D, Cugino A, Blend D, Rutecki GW, Whittier FC. Geriatric renal function: estimating glomerular filtration in an ambulatory elderly population. Clin Nephrol 1997, 47:222-28.
-
(1997)
Clin Nephrol
, vol.47
, pp. 222-228
-
-
Baracskay, D.1
Jarjoura, D.2
Cugino, A.3
Blend, D.4
Rutecki, G.W.5
Whittier, F.C.6
-
73
-
-
0242490542
-
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
-
10.1056/NEJMoa032292, 14610160, Valsartan in Acute Myocardial Infarction Trial Investigators
-
Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM, . Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-906. 10.1056/NEJMoa032292, 14610160, Valsartan in Acute Myocardial Infarction Trial Investigators.
-
(2003)
N Engl J Med
, vol.349
, pp. 1893-1906
-
-
Pfeffer, M.A.1
McMurray, J.J.V.2
Velazquez, E.J.3
Rouleau, J.L.4
Køber, L.5
Maggioni, A.P.6
Solomon, S.D.7
Swedberg, K.8
Van de Werf, F.9
White, H.10
Leimberger, J.D.11
Henis, M.12
Edwards, S.13
Zelenkofske, S.14
Sellers, M.A.15
Califf, R.M.16
-
74
-
-
1442348810
-
Implementation of guidelines for the prevention of diabetic nephropathy
-
10.2337/diacare.27.3.803, 14988308
-
Fagerudd J, Forsblom C, Pettersson-Fernholm K, Groop PH. Implementation of guidelines for the prevention of diabetic nephropathy. Diabetes Care 2004, 27:803-804. 10.2337/diacare.27.3.803, 14988308.
-
(2004)
Diabetes Care
, vol.27
, pp. 803-804
-
-
Fagerudd, J.1
Forsblom, C.2
Pettersson-Fernholm, K.3
Groop, P.H.4
-
75
-
-
33746764463
-
Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings
-
10.1097/01.hjh.0000239303.93872.31, 16877970
-
Minutolo R, Sasso FC, Chiodini P, Cianciaruso B, Carbonara O, Zamboli P, Tirino G, Pota A, Torella R, Conte G, De Nicola L. Management of cardiovascular risk factors in advanced type 2 diabetic nephropathy: a comparative analysis in nephrology, diabetology and primary care settings. J Hypertens 2006, 24:1655-61. 10.1097/01.hjh.0000239303.93872.31, 16877970.
-
(2006)
J Hypertens
, vol.24
, pp. 1655-1661
-
-
Minutolo, R.1
Sasso, F.C.2
Chiodini, P.3
Cianciaruso, B.4
Carbonara, O.5
Zamboli, P.6
Tirino, G.7
Pota, A.8
Torella, R.9
Conte, G.10
De Nicola, L.11
|